Consolidated Statements of Operations - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Product revenue	$ 1,852,017	$ 1,500,722
Cost of product sales	771,005	618,099
Gross profit	1,081,012	882,623
Operating expenses
Research and development	504,239	322,165
Sales and marketing	733,913	500,255
General and administrative	1,335,292	1,220,705
Total operating expenses	2,573,444	2,043,125
Operating loss	(1,492,432)	(1,160,502)
Other income
Interest income	1,919	8,237
Net Loss	(1,490,513)	(1,152,265)
Net loss attributable to non-controlling interest	263,685	120,783
Net Loss attributable to BioLife Solutions, Inc.	$ (1,226,828)	$ (1,031,482)
Basic and diluted net loss per common share attributable to BioLife Solutions, Inc. (in dollars per share)	$ (0.10)	$ (0.09)
Basic and diluted weighted average common shares used to calculate net loss per common share (in dollars per share)	12,457,858	12,100,588